"What should I eat?" is perhaps the most common question patients with inflammatory bowel disease ask their doctors.

MRM Health has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) ...

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...

A new cohort study from Northern Denmark finds that mild-onset Crohn's disease (CD) has worse 10-year probability of progression to moderate-severe disease, at 53%, than that of mild-onset ulcerative ...

Medically reviewed by Qin Rao, MD Key Takeaways Clinical remission means symptoms are mostly gone, but inflammation may still ...

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) ...

Researchers from the Medical University of Lodz in Poland investigated how diet can affect the severity of inflammatory bowel disease (IBD). IBD includes Crohn’s disease and ulcerative colitis, which ...

Ulcerative colitis is a chronic condition characterized by inflammation and ulcers in the colon. Research is ongoing to expand treatment options. A study published in the New England Journal of ...

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug ...